Cardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2024 Results Earnings Conference Call May 2, 2024 4:30 PM ET
Company Participants
Kiki Patel - Investor Relations, Gilmartin Group
Mark Erlander - Chief Executive Officer
Jamie Levine - Chief Financial Officer
Conference Call Participants
Mark Frahm - TD Cowen
Joseph Catanzaro - Piper Sandler
Andy Hsieh - William Blair
Operator
Welcome to the Cardiff Oncology First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.
I would now like to turn the conference call over to Kiki Patel of Gilmartin Group. Please go ahead.
Kiki Patel
Thank you, operator. Joining us on the call today from Cardiff Oncology are Chief Executive Officer, Mark Erlander, and Chief Financial Officer, Jamie Levine.
During this conference call, management will make forward-looking statements including, without limitations, statements related to guidance, results, and the timing of the data readouts for onvansertib clinical trials.
These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties.
Factors that could cause results to be different from these statements include factors the company describes in the section entitled Risk Factors in our annual report on Form 10-K filed with the SEC for the year ended December 31, 2023. Cardiff Oncology undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations.
With that, I will turn the call over to Chief Executive Officer, Mark Erlander. Mark?
Mark Erlander
Well, thank you Kiki. And good afternoon, everyone. And thank you for joining our conference call for the first quarter of 2024 business update. It was less than a year ago that we announced that our clinical development plan for onvansertib would focus on the first line treatment of rat mutated metastatic colorectal cancer or mCRC. The data we shared last August supported this move and our focus on first line mCRC addresses a large patient, almost 50,000 new patients a year in the United States, for whom there have been no new therapies approved in 20 years.
In the first quarter of 2024, three data sets added to the body of evidence supporting our first line focus strategy. First was the ONSEMBLE data, which served as an independent and randomized data set that replicated the efficacy signals in bev naïve patients observed in our Phase 1b/2 trial.